SCHEMBL2812150

SCHEMBL2812150

COc1ccc(CN2CCc3nn(C)c4nc(NCCNC(C)=O)nc2c34)cc1

nearest known ligand 0.39

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 3/20 0.39
SCD O00767 3/20 0.38
CDK2 P24941 2/20 0.37
CCNE2 O96020 1/20 0.37
CCNE1 P24864 1/20 0.37
BCDIN3D Q7Z5W3 1/20 0.37
CNR2 P34972 1/20 0.37
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
ALOX15 P16050 1/20 0.36
CYP2C19 P33261 2/20 0.36
ALDH1A1 P00352 1/20 0.36
CYP1A2 P05177 1/20 0.36
SHMT2 P34897 1/20 0.35
AURKA O14965 1/20 0.35
CCNA2 P20248 1/20 0.35
CCNA1 P78396 1/20 0.35
BCHE P06276 1/20 0.35
CHRM1 P11229 1/20 0.35
ACHE P22303 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2813905 0.88 ACHE (0.40) SMN1; SMN2CNR2BCHECHRM1ACHE
SCHEMBL2814487 0.87 BCDIN3D (0.40) SMN1; SMN2CDK2CCNE2CCNE1BCDIN3D
SCHEMBL13131652 0.85 SHMT2 (0.48) CDK2CCNE2CCNE1BCDIN3DGAA
SCHEMBL2809950 0.84 BCDIN3D (0.38) SMN1; SMN2CDK2CCNE2CCNE1BCDIN3D
SCHEMBL2809534 0.83 MAPT (0.40) SMN1; SMN2BCDIN3DCNR2GAACYP2C19
SCHEMBL2816716 0.83 CCNE2 (0.37) SMN1; SMN2CDK2CCNE2CCNE1BCDIN3D
SCHEMBL2812793 0.83 HRH1 (0.47) BCDIN3DACHE
SCHEMBL2809862 0.82 PIK3CA (0.47) SMN1; SMN2MAPK1ALDH1A1
SCHEMBL2809426 0.82 HRH1 (0.39) BCDIN3DALDH1A1SHMT2
SCHEMBL2809482 0.82 SMN1; SMN2 (0.45) SMN1; SMN2GAAMAPK1ALOX15CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-8343983-B2 Substituted pyrazolo-pyrimidine compounds ARQULE, INC. (US) 2013-01-01 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS ARQULE, INC. (US) 2010-09-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100249110-A1 SUBSTITUTED PYRAZOLO-PYRIMIDINE COMPOUNDS DPYD, TYMP, TP53 SMN1; SMN2 2524/4885SCD 3916/4885CDK2 8/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.